The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
The pharmacology of second-generation chimeric antigen receptors
Open accessAbstract
Second-generation chimeric antigen receptors (CARs) retarget and reprogramme T cells to augment their antitumour efficacy. The combined activating and co-stimulatory domains incorporated in these CARs critically determine the function, differentiation, metabolism and persistence of engineered T cells. CD19-targeted CARs that incorporate CD28 or 4-1BB signalling domains are the best known to date. Both have shown remarkable complete remission rates in patients with refractory B cell malignancies. Recent data indicate that CD28-based CARs direct a brisk proliferative response and boost effector functions, whereas 4-1BB-based CARs induce a more progressive T cell accumulation that may compensate for less immediate potency. These distinct kinetic features can be exploited to further develop CAR-based T cell therapies for a variety of cancers. A new field of immunopharmacology is emerging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
ZINKERNAGEL, R. M., & DOHERTY, P. C. (1974) · Nature · doi:10.1038/248701a0 · Cited by 2,095
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationTrans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
The CD28 Signaling Pathway Regulates Glucose Metabolism
Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H., & Thompson, C. B. (2002) · Immunity · doi:10.1016/s1074-7613(02)00323-0 · Cited by 1,475
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
Watts, T. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115839 · Cited by 1,353
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Self-citationDifferential T Cell Costimulatory Requirements in CD28-Deficient Mice
Shahinian, A., Pfeffer, K., Lee, K. P., Kündig, T. M., Kishihara, K., Wakeham, A., Kawai, K., Ohashi, P. S., Thompson, C. B., & Mak, T. W. (1993) · Science · doi:10.1126/science.7688139 · Cited by 1,257
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Self-citationSavoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds
Viola, A., & Lanzavecchia, A. (1996) · Science · doi:10.1126/science.273.5271.104 · Cited by 1,023
Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
ICOS co-stimulatory receptor is essential for T-cell activation and function
Dong, C., Juedes, A. E., Temann, U.-A., Shresta, S., Allison, J. P., Ruddle, N. H., & Flavell, R. A. (2001) · Nature · doi:10.1038/35051100 · Cited by 936
The role of TNF superfamily members in T-cell function and diseases
Croft, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2526 · Cited by 920
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Self-citationJacobs, S. R., Herman, C. E., MacIver, N. J., Wofford, J. A., Wieman, H. L., Hammen, J. J., & Rathmell, J. C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4476 · Cited by 850
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Irving, B. A., & Weiss, A. (1991) · Cell · doi:10.1016/0092-8674(91)90314-o · Cited by 805
Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.47 · Cited by 804
Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system.
Aruffo, A., & Seed, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8573 · Cited by 784
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
CD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775
T-helper-1-cell cytokines drive cancer into senescence
Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Self-citationICOS is essential for effective T-helper-cell responses
Tafuri, A., Shahinian, A., Bladt, F., Yoshinaga, S. K., Jordana, M., Wakeham, A., Boucher, L.-M., Bouchard, D., Chan, V. S. F., Duncan, G., et al. (2001) · Nature · doi:10.1038/35051113 · Cited by 675
Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
Self-citationComparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function.
Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P., & Hodes, R. J. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.2.631 · Cited by 669
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 590
Transfer of specificity by murine α and β T-cell receptor genes
DembiĆ, Z., Haas, W., Weiss, S., McCubrey, J., Kiefer, H., von Boehmer, H., & Steinmetz, M. (1986) · Nature · doi:10.1038/320232a0 · Cited by 579
Adusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572
Self-citationHoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T., & Thompson, C. B. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.12.4472 · Cited by 566
Li, Y. S., Hayakawa, K., & Hardy, R. R. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.951 · Cited by 559
Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.
Gimmi, C. D., Freeman, G. J., Gribben, J. G., Gray, G., & Nadler, L. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6586 · Cited by 548
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Self-citationGrowth factors can influence cell growth and survival through effects on glucose metabolism
Vander Heiden, M. G., Plas, D. R., Rathmell, J. C., Fox, C. J., Harris, M. H., & Thompson, C. B. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5899-5912.2001 · Cited by 536
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Self-citationHudecek, M., Sommermeyer, D., Kosasih, P. L., Silva-Benedict, A., Liu, L., Rader, C., Jensen, M. C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0127 · Cited by 532
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Jensen, M. C., Popplewell, L., Cooper, L. J., DiGiusto, D., Kalos, M., Ostberg, J. R., & Forman, S. J. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.014 · Cited by 529
Cruz, C. R. Y., Micklethwaite, K. P., Savoldo, B., Ramos, C. A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A. J., Ito, S., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506741 · Cited by 508
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4174 · Cited by 496
Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch
Gubser, P. M., Bantug, G. R., Razik, L., Fischer, M., Dimeloe, S., Hoenger, G., Durovic, B., Jauch, A., & Hess, C. (2013) · Nature Immunology · doi:10.1038/ni.2687 · Cited by 493
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
Early Transcription and Silencing of Cytokine Genes Underlie Polarization of T Helper Cell Subsets
Grogan, J. L., Mohrs, M., Harmon, B., Lacy, D. A., Sedat, J. W., & Locksley, R. M. (2001) · Immunity · doi:10.1016/s1074-7613(01)00103-0 · Cited by 485
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
Self-citationRathmell, J. C., Heiden, M. G. V., Harris, M. H., Frauwirth, K. A., & Thompson, C. B. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00066-6 · Cited by 467
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
Self-citationFinney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 467
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintás-Cardama, A., Larson, S. M., & Sadelain, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0674 · Cited by 463
Self-citationIL-7 Enhances the Survival and Maintains the Size of Naive T Cells
Rathmell, J. C., Farkash, E. A., Gao, W., & Thompson, C. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6869 · Cited by 459
Cytokine Signals Are Sufficient for HIV-1 Infection of Resting Human T Lymphocytes
Unutmaz, D., KewalRamani, V. N., Marmon, S., & Littman, D. R. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1735 · Cited by 427
Inducible T cell antigen 4-1BB. Analysis of expression and function
Pollok, K. E., Kim, Y. J., Zhou, Z., Hurtado, J., Kim, K. K., Pickard, R. T., & Kwon, B. S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.3.771 · Cited by 421
cDNA sequences of two inducible T-cell genes.
Kwon, B. S., & Weissman, S. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.6.1963 · Cited by 401
Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides
Romeo, C., & Seed, B. (1991) · Cell · doi:10.1016/0092-8674(91)90327-u · Cited by 396
Yang, K., Shrestha, S., Zeng, H., Karmaus, P. W. F., Neale, G., Vogel, P., Guertin, D. A., Lamb, R. F., & Chi, H. (2013) · Immunity · doi:10.1016/j.immuni.2013.09.015 · Cited by 394
Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal
Takahashi, C., Mittler, R. S., & Vella, A. T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5037 · Cited by 379
Identification of the Earliest B Lineage Stage in Mouse Bone Marrow
Li, Y.-S., Wasserman, R., Hayakawa, K., & Hardy, R. R. (1996) · Immunity · doi:10.1016/s1074-7613(00)80268-x · Cited by 376
Krause, A., Guo, H.-F., Latouche, J.-B., Tan, C., Cheung, N.-K. V., & Sadelain, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.619 · Cited by 365
Self-citationMelero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S., & Chen, L. (1998) · Cellular Immunology · doi:10.1006/cimm.1998.1396 · Cited by 363
Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Leming, P., Puzanov, I., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 359
Jenkins, M. K., Chen, C. A., Jung, G., Mueller, D. L., & Schwartz, R. H. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.1.16 · Cited by 357
Arch, R. H., & Thompson, C. B. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.558 · Cited by 356
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
Song, D.-G., Ye, Q., Poussin, M., Harms, G. M., Figini, M., & Powell, D. J. (2012) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 355
Cannons, J. L., Lau, P., Ghumman, B., DeBenedette, M. A., Yagita, H., Okumura, K., & Watts, T. H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1313 · Cited by 355
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 353
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor-Papadimitriou, J., Burchell, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4901 · Cited by 346
Diehn, M., Alizadeh, A. A., Rando, O. J., Liu, C. L., Stankunas, K., Botstein, D., Crabtree, G. R., & Brown, P. O. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092284399 · Cited by 337
Goodwin, R. G., Din, W. S., Davis‐Smith, T., Anderson, D. M., Gimpel, S. D., Sato, T. A., Maliszewski, C. R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., et al. (1993) · European Journal of Immunology · doi:10.1002/eji.1830231037 · Cited by 334
Chang, Y.-H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Frigault, M. J., Lee, J., Basil, M. C., Carpenito, C., Motohashi, S., Scholler, J., Kawalekar, O. U., Guedan, S., McGettigan, S. E., Posey, A. D., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0186 · Cited by 323
CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
Saoulli, K., Lee, S. Y., Cannons, J. L., Yeh, W. C., Santana, A., Goldstein, M. D., Bangia, N., DeBenedette, M. A., Mak, T. W., Choi, Y., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1849 · Cited by 322
Kopf, M., Ruedl, C., Schmitz, N., Gallimore, A., Lefrang, K., Ecabert, B., Odermatt, B., & Bachmann, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80144-2 · Cited by 321
Costimulation of CD28- T lymphocytes by 4-1BB ligand
DeBenedette, M. A., Shahinian, A., Mak, T. W., & Watts, T. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.2.551 · Cited by 320
Guest, R. D., Hawkins, R. E., Kirillova, N., Cheadle, E. J., Arnold, J., O'Neill, A., Irlam, J., Chester, K. A., Kemshead, J. T., Shaw, D. M., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000161397.96582.59 · Cited by 318
Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines
Kane, L. P., Andres, P. G., Howland, K. C., Abbas, A. K., & Weiss, A. (2001) · Nature Immunology · doi:10.1038/83144 · Cited by 316
Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316
Self-citationMonoclonal antibodies identifying a novel T-Cell antigen and Ia antigens of human lymphocytes
Hansen, J. A., Martin, P. J., & Nowinski, R. C. (1980) · Immunogenetics · doi:10.1007/bf01561573 · Cited by 314
T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins.
Letourneur, F., & Klausner, R. D. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.8905 · Cited by 307
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
Riley, J. L., Mao, M., Kobayashi, S., Biery, M., Burchard, J., Cavet, G., Gregson, B. P., June, C. H., & Linsley, P. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162359999 · Cited by 307
Nolte, M. A., Van Olffen, R. W., Van Gisbergen, K. P. J. M., & Van Lier, R. A. W. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00774.x · Cited by 305
Hombach, A., Wieczarkowiecz, A., Marquardt, T., Heuser, C., Usai, L., Pohl, C., Seliger, B., & Abken, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6123 · Cited by 299
Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes.
Brocker, T., & Karjalainen, K. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1653 · Cited by 296
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Self-citationWeng, N.-P., Araki, Y., & Subedi, K. (2012) · Nature Reviews Immunology · doi:10.1038/nri3173 · Cited by 290
Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
An Enigmatic Tail of CD28 Signaling
Boomer, J. S., & Green, J. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002436 · Cited by 283
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells
Futagawa, T., Akiba, H., Kodama, T., Takeda, K., Hosoda, Y., Yagita, H., & Okumura, K. (2002) · International Immunology · doi:10.1093/intimm/14.3.275 · Cited by 283
DeBenedette, M. A., Wen, T., Bachmann, M. F., Ohashi, P. S., Barber, B. H., Stocking, K. L., Peschon, J. J., & Watts, T. H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4833 · Cited by 282
Molecular Cloning of the Zeta Chain of the T Cell Antigen Receptor
Weissman, A. M., Baniyash, M., Hou, D., Samelson, L. E., Burgess, W. H., & Klausner, R. D. (1988) · Science · doi:10.1126/science.3278377 · Cited by 278
Advances in targeting cell surface signalling molecules for immune modulation
Yao, S., Zhu, Y., & Chen, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3877 · Cited by 267
ICOS Controls the Pool Size of Effector-Memory and Regulatory T Cells
Burmeister, Y., Lischke, T., Dahler, A. C., Mages, H. W., Lam, K.-P., Coyle, A. J., Kroczek, R. A., & Hutloff, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.774 · Cited by 267
Bridgeman, J. S., Hawkins, R. E., Bagley, S., Blaylock, M., Holland, M., & Gilham, D. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901766 · Cited by 267
The Inducible Costimulator (ICOS) Is Critical for the Development of Human T H 17 Cells
Paulos, C. M., Carpenito, C., Plesa, G., Suhoski, M. M., Varela-Rohena, A., Golovina, T. N., Carroll, R. G., Riley, J. L., & June, C. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000448 · Cited by 255
James, S. E., Greenberg, P. D., Jensen, M. C., Lin, Y., Wang, J., Till, B. G., Raubitschek, A. A., Forman, S. J., & Press, O. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.7028 · Cited by 249
Peach, R. J., Bajorath, J., Brady, W., Leytze, G., Greene, J., Naemura, J., & Linsley, P. S. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2049 · Cited by 248
Cooper, L. J. N., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1989 · Cited by 248
The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 245
Self-citationMoslecular and biological characterization of human 4‐1BB and its ligands
Alderson, M. R., Smith, C. A., Tough, T. W., Davis‐Smith, T., Armitage, R. J., Falk, B., Roux, E., Baker, E., Sutherland, G. R., Din, W. S., et al. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240943 · Cited by 244
Gong, M. C., Latouche, J.-B., Krause, A., Heston, W. D. W., Bander, N. H., & Sadelain, M. (1999) · Neoplasia · doi:10.1038/sj.neo.7900018 · Cited by 241
Self-citationHauer, J., Püschner, S., Ramakrishnan, P., Simon, U., Bongers, M., Federle, C., & Engelmann, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500187102 · Cited by 240
Costimulation of T cells by OX40, 4-1BB, and CD27
Croft, M. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00025-x · Cited by 231
Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells
Wilcox, R. A., Chapoval, A. I., Gorski, K. S., Otsuji, M., Shin, T., Flies, D. B., Tamada, K., Mittler, R. S., Tsuchiya, H., Pardoll, D. M., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4262 · Cited by 231
Metabolism of activated T lymphocytes
Maciolek, J. A., Alex Pasternak, J., & Wilson, H. L. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.006 · Cited by 224
Bour‐Jordan, H., & Bluestone, J. A. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00775.x · Cited by 223
Plunkett, F. J., Franzese, O., Finney, H. M., Fletcher, J. M., Belaramani, L. L., Salmon, M., Dokal, I., Webster, D., Lawson, A. D. G., & Akbar, A. N. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7710 · Cited by 222
Mitigating the toxic effects of anticancer immunotherapy
Gangadhar, T. C., & Vonderheide, R. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.245 · Cited by 222
Immune Responses in 4-1BB (CD137)-Deficient Mice
Kwon, B. S., Hurtado, J. C., Lee, Z. H., Kwack, K. B., Seo, S. K., Choi, B. K., Koller, B. H., Wolisi, G., Broxmeyer, H. E., & Vinay, D. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5483 · Cited by 221
Pollok, K. E., Kim, Y., Hurtado, J., Zhou, Z., Kim, K. K., & Kwon, B. S. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240215 · Cited by 218
Wang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C. G., Till, B., Raubitschek, A., Forman, S. J., Qian, X., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.028 · Cited by 213
Hendriks, J., Xiao, Y., Rossen, J. W. A., van der Sluijs, K. F., Sugamura, K., Ishii, N., & Borst, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1665 · Cited by 212
Wen, T., Bukczynski, J., & Watts, T. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4897 · Cited by 207
Zheng, C., Kabaleeswaran, V., Wang, Y., Cheng, G., & Wu, H. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.03.009 · Cited by 205
CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response
Radvanyi, L. G., Shi, Y., Vaziri, H., Sharma, A., Dhala, R., Mills, G. B., & Miller, R. G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.5.1788 · Cited by 194
Loskog, A., Giandomenico, V, Rossig, C., Pule, M., Dotti, G., & Brenner, M. K. (2006) · Leukemia · doi:10.1038/sj.leu.2404366 · Cited by 192
Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., Harrop, K., Whiting, N., & Drachman, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3017 · Cited by 188
Bcl-6 directly represses the gene program of the glycolysis pathway
Oestreich, K. J., Read, K. A., Gilbertson, S. E., Hough, K. P., McDonald, P. W., Krishnamoorthy, V., & Weinmann, A. S. (2014) · Nature Immunology · doi:10.1038/ni.2985 · Cited by 186
Davila, M. L., Kloss, C. C., Gunset, G., & Sadelain, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061338 · Cited by 185
Self-citationThe Pim kinases control rapamycin-resistant T cell survival and activation
Fox, C. J., Hammerman, P. S., & Thompson, C. B. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042020 · Cited by 185
Brocker, T. (2000) · Blood · doi:10.1182/blood.v96.5.1999 · Cited by 181
Induction, binding specificity and function of human ICOS
Beier, K. C., Hutloff, A., Dittrich, A., Heuck, C. J., Rauch, A. M., Büchner, K., Ludewig, B., Ochs, H. D., Mages, H. W., & Kroczek, R. A. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200012)30:12<3707::aid-immu3707>3.0.co;2-q · Cited by 180
Human 4-1BB (CD137) Signals Are Mediated by TRAF2 and Activate Nuclear Factor-κB
Jang, I. K., Lee, Z. H., Kim, Y. J., Kim, S. H., & Kwon, B. S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.8016 · Cited by 176
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A., Sanmamed, M. F., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2065 · Cited by 176
A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory
Murayama, A., Sakura, K., Nakama, M., Yasuzawa‐Tanaka, K., Fujita, E., Tateishi, Y., Wang, Y., Ushijima, T., Baba, T., Shibuya, K., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601012 · Cited by 175
Gallardo, H. F., Tan, C., Ory, D., & Sadelain, M. (1997) · Blood · doi:10.1182/blood.v90.3.952 · Cited by 170
Self-citationIFN-γ– and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers
Zhang, B., Karrison, T., Rowley, D. A., & Schreiber, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33522 · Cited by 167
Sabbagh, L., Pulle, G., Liu, Y., Tsitsikov, E. N., & Watts, T. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8093 · Cited by 167
Tammana, S., Huang, X., Wong, M., Milone, M. C., Ma, L., Levine, B. L., June, C. H., Wagner, J. E., Blazar, B. R., & Zhou, X. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.122 · Cited by 165
Frecha, C., Costa, C., Nègre, D., Gauthier, E., Russell, S. J., Cosset, F.-L., & Verhoeyen, E. (2008) · Blood · doi:10.1182/blood-2008-05-155945 · Cited by 164
Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction
Ho, W., Blattman, J. N., Dossett, M. L., Yee, C., & Greenberg, P. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00113-2 · Cited by 157
Gross, J. A., John, T. S., & Allison, J. P. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.8.3201 · Cited by 154
Hombach, A. A., & Abken, H. (2011) · International Journal of Cancer · doi:10.1002/ijc.25960 · Cited by 152
Topp, M. S., Riddell, S. R., Akatsuka, Y., Jensen, M. C., Blattman, J. N., & Greenberg, P. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021288 · Cited by 144
IL-15-Dependent Induction of 4-1BB Promotes Antigen-Independent CD8 Memory T Cell Survival
Pulle, G., Vidric, M., & Watts, T. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2739 · Cited by 143
Hussein, M. A., Berenson, J. R., Niesvizky, R., Munshi, N. C., Matouš, J., Sobecks, R. M., Harrop, K. L., Drachman, J. G., & Whiting, N. C. (2010) · Haematologica · doi:10.3324/haematol.2009.008003 · Cited by 142
Kofler, D. M., Chmielewski, M. M., Rappl, G., Hombach, A., Riët, T., Schmidt, A., Hombach, A. A., Wendtner, C., & Abken, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.9 · Cited by 141
Memory CD8+ T Cells Require CD28 Costimulation
Borowski, A. B., Boesteanu, A. C., Mueller, Y. M., Carafides, C., Topham, D. J., Altman, J. D., Jennings, S. R., & Katsikis, P. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6494 · Cited by 141
ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages
Schwarz, H., Valbracht, J., Tuckwell, J., von Kempis, J., & Lotz, M. (1995) · Blood · doi:10.1182/blood.v85.4.1043.bloodjournal8541043 · Cited by 141
FLEISCHER, J., Soeth, E., Reiling, N., Grage‐Griebenow, E., Flad, H.-D., & Ernst, M. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-785.x · Cited by 134
Uncoupling T‐cell expansion from effector differentiation in cell‐based immunotherapy
Crompton, J. G., Sukumar, M., & Restifo, N. P. (2013) · Immunological Reviews · doi:10.1111/imr.12135 · Cited by 125
Signals from CD28 Induce Stable Epigenetic Modification of the IL-2 Promoter
Thomas, R. M., Gao, L., & Wells, A. D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4639 · Cited by 122
Functional Dichotomy between OX40 and 4-1BB in Modulating Effector CD8 T Cell Responses
Lee, S., Park, Y., Song, A., Cheroutre, H., Kwon, B. S., & Croft, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4464 · Cited by 120
c-Rel Is Required for Chromatin Remodeling Across the IL-2 Gene Promoter
Rao, S., Gerondakis, S., Woltring, D., & Shannon, M. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3724 · Cited by 120
Furman, R. R., Forero, A., Shustov, A. R., & Drachman, J. G. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903440946 · Cited by 118
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Almåsbak, H., Walseng, E., Kristian, A., Myhre, M. R., Inderberg, E. M., Munthe, L. A., Andersen, J. T., WANG, M. Y., Kvalheim, G., Gaudernack, G., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.4 · Cited by 117
Kohn, D. B., Dotti, G., Brentjens, R. J., Savoldo, B., Jensen, M. C., Cooper, L. J. N., June, C. H., Rosenberg, S. A., Sadelain, M., & Heslop, H. E. (2011) · Molecular Therapy · doi:10.1038/mt.2011.1 · Cited by 117
Self-citationAdoptive Therapy With Chimeric Antigen Receptor–Modified T Cells of Defined Subset Composition
Riddell, S. R., Sommermeyer, D., Berger, C., Liu, L., Balakrishnan, A., Salter, A. I., Hudecek, M., Maloney, D. G., & Turtle, C. J. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000036 · Cited by 114
Expression and function of 4‐1BB during CD4 versus CD8 T cell responses in vivo
Dawicki, W., & Watts, T. H. (2004) · European Journal of Immunology · doi:10.1002/eji.200324278 · Cited by 112
Matsushita, H., Hosoi, A., Ueha, S., Abe, J., Fujieda, N., Tomura, M., Maekawa, R., Matsushima, K., Ohara, O., & Kakimi, K. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0098 · Cited by 112
Lehner, M., Götz, G., Proff, J., Schaft, N., Dörrie, J., Full, F., Ensser, A., Muller, Y. A., Cerwenka, A., Abken, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031210 · Cited by 111
NKG2D CARs as Cell Therapy for Cancer
Sentman, C. L., & Meehan, K. R. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000029 · Cited by 111
Hildebrand, J. M., Yi, Z., Buchta, C. M., Poovassery, J., Stunz, L. L., & Bishop, G. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01055.x · Cited by 110
Drenkard, D., Becke, F. M., Langstein, J., Spruß, T., Kunz‐Schughart, L. A., Tan, T. E., Lim, Y. C., & Schwarz, H. (2006) · The FASEB Journal · doi:10.1096/fj.05-4739com · Cited by 110
Song, D.-G., Ye, Q., Santoro, S. P., Fang, C., Best, A. J., & Powell, D. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.143 · Cited by 108
de Vos, S., Forero, A., Ansell, S. M., Kahl, B. S., Cheson, B. D., Bartlett, N. L., Furman, R. R., Winter, J. N., Kaplan, H. G., Timmerman, J. M., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-44 · Cited by 105
Fuse, S., Zhang, W., & Usherwood, E. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.1148 · Cited by 104
Santoro, S. P., Kim, S., Motz, G. T., Alatzoglou, D., Li, C., Irving, M. B., Powell, D. J., & Coukos, G. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0192 · Cited by 102
Liadi, I., Singh, H., Romain, G., Rey-Villamizar, N., Merouane, A., Adolacion, J. R. T., Kebriaei, P., Huls, H. M., Qiu, P., Roysam, B., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0195 · Cited by 102
How do CARs work? Early insights from recent clinical studies targeting CD19
Davila, M. L., Brentjens, R. J., Wang, X., Rivière, I., & Sadelain, M. (2012) · OncoImmunology · doi:10.4161/onci.22524 · Cited by 102
Self-citationShen, C.-J., Yang, Y.-X., Han, E. Q., Cao, N., Wang, Y.-F., Wang, Y., Zhao, Y.-Y., Zhao, L.-M., Cui, J., Gupta, P. K., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-33 · Cited by 100
Human eosinophils express and release IL-13 following CD28-dependent activation
Woerly, G., Lacy, P., Younes‐Chennoufi, A. B., Roger, N., Loiseau, S., Moqbel, R., & Capron, M. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.4.769 · Cited by 98
Opposing Roles for TRAF1 in the Alternative versus Classical NF-κB Pathway in T Cells
McPherson, A. J., Snell, L. M., Mak, T. W., & Watts, T. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.350538 · Cited by 98
Sequence, structure, function, immunity: structural genomics of costimulation
Chattopadhyay, K., Lázár‐Molnár, E., Yan, Q., Rubinstein, R., Zhan, C., Vigdorovich, V. I., Ramagopal, U. A., Bonanno, J. B., Nathenson, S. G., & Almo, S. C. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00778.x · Cited by 95
Chimeric Antigen Receptor Therapy for B-cell Malignancies
Porter, D. L., Kalos, M. D., Zheng, Z., Levine, B. L., & June, C. H. (2011) · Journal of Cancer · doi:10.7150/jca.2.331 · Cited by 93
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citationNF-κB in biology and targeted therapy: new insights and translational implications
Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01757-9 · Cited by 2,047
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Metadata
- Authors
- van der Stegen, S. J. C., Hamieh, M., & Sadelain, M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-07
- Volume
- 14
- Issue
- 7
- Pages
- 499-509
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1604141497
- Cited by
- 555
- References
- 240
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.